

Elisa Sottotetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7982565/publications.pdf>

Version: 2024-02-01

12
papers

265
citations

933447

10
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

690
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
2	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	7.0	67
3	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 792-798.	1.0	21
4	Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. <i>BMC Cancer</i> , 2018, 18, 841.	2.6	13
5	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017, 17, 331-336.	2.0	10
6	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 83-103.	1.6	10
7	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	1.1	18
8	Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication. <i>Wound Repair and Regeneration</i> , 2016, 24, 1036-1040.	3.0	2
9	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
10	Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8884-8895.	4.1	13
11	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	2.4	52
12	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. <i>Cancers</i> , 2014, 6, 1753-1768.	3.7	14